Skip to main content

Market Overview

FDA Ruling Shakes Up Biotech: Gilead, AbbVie And More

  • Biotechs have had a tough week. On Wednesday, stocks plummeted after Citron Research released a new report classifying Valeant Pharmaceuticals Intl Inc (NYSE: VRX) as a "pharmaceutical Enron."
  • On Thursday, shares continued to tumble on the news and an FDA report warning that AbbVie Inc (NYSE: ABBV)'s Viekira Pak and Technivie could cause serious liver injury.

Many major biotech stocks tumbled after the FDA warned AbbVie’s Viekira Pak and Technivie, used to treat hepatitis C, could cause serious liver injury, especially in patients with underlying advanced liver disease.

As a result, shares of AbbVie fell 10.33 percent on Thursday. However, one stock benefited from the news: Gilead Sciences, Inc. (NASDAQ: GILD), which rose 5.77 percent.

Viekira Pak was worrying Gilead investors, as the drug offered a cheaper option to Gilead’s Hepatitis C treatment. Now the path may be clearer for Gilead’s Harvoni, which now looks safer than Viekira or Technivie.

Related Link: Noted Biotech Analyst Doesn't Think Valeant And Horizon Are Frauds, But Did Push A Line

Other stocks on the decline include:

  • Valeant Pharmaceuticals Intl Inc (NYSE: VRX), down 7.08 percent
  • Horizon Pharma PLC (NASDAQ: HZNP), down 11.53 percent
  • Express Scripts Holding Company (NASDAQ: ESRX), down 4.13 percent
  • Enanta Pharmaceuticals Inc (NASDAQ: ENTA), down 40.62 percent

Disclosure: Javier Hasse holds no positions in any of the securities mentioned above.


Related Articles (GILD + ABBV)

View Comments and Join the Discussion!

Posted-In: Biotech Long Ideas News Short Sellers FDA Movers Trading Ideas General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at